Spectris (Surrey, UK) - the parent company of PANalytical - has acquired the business and assets of the Canadian company La Corporation Scientifique Claisse Inc., a provider of sample preparation products for atomic spectroscopy (including X-ray) analysis.
Spectris (Surrey, UK) — the parent company of PANalytical — has acquired the business and assets of the Canadian company La Corporation Scientifique Claisse Inc., a provider of sample preparation products for atomic spectroscopy (including X-ray) analysis.
Claisse designs, manufactures, and sells consumables and instruments used to prepare samples for spectroscopic analysis in mining, pharmaceutical, academic research, and industrial applications. As a result of the acquisition, Claisse will become part of the materials analysis segment of Spectris and will be integrated into PANalytical (Almelo, Netherlands).
PANalytical employs more than 1000 people worldwide. Application laboratories are located in Japan, China, the US, Brazil, and the Netherlands. PANalytical’s research activities are based in Almelo, the Netherlands, and on the campus of the University of Sussex in Brighton (UK). Supply and competence centers are located on two sites in the Netherlands – Almelo (development and production of X-ray instruments) and Eindhoven (development and production of X-ray tubes) — as well as in Nottingham, UK (development of XRF applications and standards) and in Boulder, Colorado (development and production of near-infrared instruments).
An Interview with AES Mid-Career Award Recipient Jason Dwyer
July 25th 2024Jason Dwyer of the University of Rhode Island has been named the recipient of the American Electrophoresis Society’s Mid-Career Award, which honors exceptional contributions to the field of electrophoresis, microfluidics, and related areas by an individual who is currently in the middle of their career.
Glucose's Impact on Brain Cancer Cells Unveiled Through Raman Imaging
July 25th 2024Researchers have used Raman spectroscopy and chemometric methods to reveal how glucose affects normal and cancerous brain cell metabolism. Their findings highlight specific biomarkers that can distinguish metabolic changes, potentially aiding in cancer research and treatment.